{"id":"NCT02085252","sponsor":"Takeda","briefTitle":"A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer","officialTitle":"An Open-Label, Multicenter, Phase III Study to Assess the Impact of Transient Androgenic Deprivation With Enantone LP 11.25 Mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06-03","primaryCompletion":"2016-11-08","completion":"2016-11-08","firstPosted":"2014-03-12","resultsPosted":"2019-04-16","lastUpdate":"2019-06-28"},"enrollment":116,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Leuprorelin","otherNames":["Enantone ®"]},{"type":"DRUG","name":"Bicalutamide","otherNames":["Casodex ®"]}],"arms":[{"label":"Leuprorelin 11.25 mg","type":"EXPERIMENTAL"},{"label":"Active surveillance","type":"NO_INTERVENTION"}],"summary":"The purpose of this study is to assess two treatment strategies (leuprorelin treatment and active surveillance without androgen deprivation) for indolent prostate cancer and to compare their therapeutic benefit for management of patients with low-risk, localized prostate cancer.","primaryOutcome":{"measure":"Number of Participants With Negative Biopsies at Month 12","timeFrame":"Month 12","effectByArm":[{"arm":"Leuprorelin 11.25 mg","deltaMin":28,"sd":null},{"arm":"Active Surveillance","deltaMin":17,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0318"}]},"eligibility":{"minAge":"50 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":2,"countries":["France"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":58},"commonTop":["Hot flush","Erectile dysfunction","Flushing","Dysuria","Libido decreased"]}}